Construction and characterization of retroviral vectors for interleukin-2 gene therapy

Journal of Immunotherapy

Volumn 20, Issue 6, 1997, Pages 437-448

  Fakhrai, Habib ^a   Shawler, Daniel L ^a   Van Beveren, Charles ^a   Lin, Hong ^a   Dorigo, Oliver ^a   Solomon, Michael J ^a   Gjerset, Ruth A ^a   Smith, Larry ^b   Bartholomew, Richard M ^b   Boggiano, César A ^a   Gold, Daniel P ^a   Sobol, Robert E ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b Orchestra Therapeutics Inc   (United States)

Author keywords

Gene transfer; Interleukin 2; Retroviral vectors

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 2; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; FIBROBLAST CULTURE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RETROVIRUS;

EID: 0030728948     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199711000-00003     Document Type: Article

References (34)

1. Gabrilove JL, Jakubowski A. Hematopoietic growth factors: biology and clinical application. Monogr JNCI 1990;10:73-7.
2. Kelso A. Cytokines: structure, function and synthesis. Curr Opin Immunol 1989;2:215-25.
3. Borden EC, Sondel PM. Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 1990;65:800-14.
4. Rosenberg SA, Lotze MT, Mule JJ. New approaches to the immunotherapy of cancer. Ann Intern Med 1988;108:853-64.
5. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 1986;256:3117-24.
6. Pizza G, Viza D, DeVince C, Vichi-Pascuuchi JM, Busutti L, Bergami T. Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study. Cytokine Res 1988;7:45-8.
7. Sarna G, Collins J, Figlin R, Robertson P, Altrock B, Abels R. A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects. J Biol Response Mod 1990;9:81-6.
8. Gandolfi L, Solmi L, Pizza GC, et al. Intratumoral echo-guided injection of interleukin-2 and cytokine-activated killer cells in hepatocellular carcinoma. Hepatogastroenterology 1989;36:352-6.
9. Bubenik J, Viotenok NN, Kieler J, et al. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol Lett 1988; 19: 279-82.
10. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 1990;60:387-403.
11. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicty and induces protective immunity. J Exp Med 1990;172:1217-23.
12. Shawler DL, Dorigo O, Van Beveren C, Bartholomew RM, Fakhrai H, Sobol RE. Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma. Oncol Rep 1997;4:135-8.
13. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989;7:980-90.
14. Cullen BR. Expression of a cloned human interleukin-2 cDNA is enhanced by the substitution of a heterologous mRNA leader region. DNA 1988;7:645-50.
15. Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983;302:305-10.
16. Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987;50:129-35.
17. Kriegler M. Gene transfer and expression, a laboratory manual. New York: Stockton Press, 1990:47-56.
18. Fakhrai H, Shawler DL, Gjerset R, et al. Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 1995;6:591-601.
19. Xu L, Yee JK, Wolff JA, Friedmann T. Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 1989;171:331-41.
20. Sobol RE, Mick R, Royston I, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987;316:1111-7.
21. Van Heijne G. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res 1986;14:4683-90.
22. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987;15:8125-48.
23. Kozak M. The scanning model for translation: an update. J Cell Biol 1989; 108:229-311.
24. Wada K, Aota S, Tsuchiya R, Ishibashi F, Gojobori T, Ikemura T. Codon usage tabulated from the GenBank genetic sequence data. Nucleic Acids Res 1990;25:2367-411.
25. Klehr D, Maas K, Bode J. Scaffold-attached regions from the human interferon beta domain can be used to enhance the stable expression of genes under the control of various promoters. Biochemistry 1991;5:1264-70.
26. Gasser SM, Laemmli UK. A glimpse at chromosomal order. Trends Genet 1987;3:16.
27. Ugozzolli L, Wallace RB. Allele-specific polymerase chain reaction. Methods 1991;2:42-8.
28. Tahara H, Zeh HJ III, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-9.
29. Tsai S-CJ, Gansbacher B, Tait L, Miller FR, Heppner GH. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. JNCI 1993;85:546-53.
30. Sobol RE, Fakhrai H, Shawler DL, et al. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2: a phase I study-clinical protocol. Hum Gene Ther 1995;6:195-204.
31. Gansbacher B, Zier K, Cronin K, et al. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood 1992;80:2817-25.
32. Weichselbaum RR, Hallahan DE, Beckett MA, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994;54:4266-9.
33. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther 1994;1:51-64.
34. Ostrove JM. Safety testing programs for gene therapy viral vectors. Cancer Gene Ther 1994;1:125-31.